Roivant Sciences shares drop as lupus treatment misses trial goal
Roivant Sciences Ltd. shares (ROIV) fell 3% premarket on Monday after the company said the experimental treatment brepocitinib failed to meet its main goal in a trial involving patients with moderate to severe lupus. Due to the high placebo response rate seen in the trial, "it was not possible to truly assess the impact of the drug, or to establish sufficient differentiation from other therapies in lupus patients," Roivant CEO Matt Gline said in a statement. Roivant will not pursue further development of brepocitinib in systemic lupus erythematosus, the most common type of lupus, Gline sad, but is still enthusiastic about the treatment's potential in an eye condition called non-infectious uveitis and dermatomyositis, an inflammatory disease that causes muscle weakness and skin rash. Roivant shares have gained 14.3% in the year to date, while the S&P 500 is up 18.8%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-27-23 0853ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks